

Check out what's new!

TAP INTO A NEW POSSIBILITY for depression

Visit [neurostar.com](#)



OCD CLEARANCE


Do you have patients with OCD in your practice who are looking for alternative treatment options? Are you interested in treating a new patient population with your NeuroStar TMS? Reach out to your Practice Development Manager (PDM) or Strategic Account Manager (SAM) today to find out more about treating OCD with NeuroStar and to schedule a training for your practice!

[READ THE PRESS RELEASE](#)

Email Your Patients


Notify your patients that you now offer OCD treatment with NeuroStar TMS by using the email template on [myneurostar.com](#) after you complete training with your PDM!


[GET THE EMAIL NOW](#)



NEUROSTAR TMS IS NOW FDA-CLEARED to treat OCD

Your Logo Here

Proudly offering  Advanced Therapy for Mental Health



Advertise OCD with Co-op Marketing

Use our approved OCD copy in your co-op advertising and submit the ads for pre-approval to [co-opmarketing@neurostar.com](#)!

- NeuroStar is FDA cleared as an adjunct treatment for adults suffering from Obsessive-Compulsive Disorder (OCD).
- If medications and psychological interventions have not worked for your OCD, it may be time to consider non-invasive NeuroStar treatment to find relief and help get your life back.
- NeuroStar Advanced Therapy not only treats Major Depressive Disorder (MDD) but can also be an adjunct for the treatment of adult patients suffering from Obsessive-Compulsive Disorder (OCD).

Make sure to include the OCD indication statement on your ads to remain compliant with FDA guidelines:

The NeuroStar Advanced Therapy system is intended to be used as an adjunct for the treatment of adult patients suffering from Obsessive-Compulsive Disorder (OCD). Visit [neurostar.com](#) for full safety and prescribing information.

OCD Insurance Coverage

TMS is a widely reimbursed treatment for MDD across the country. It is estimated that 95% of private payor covered lives can be reimbursed by insurance, with 61 million lives covered by Medicare.

With the new NeuroStar OCD Indication, we've been monitoring health policies closely. We are happy to report there is nationwide coverage for TMS as a treatment for OCD through Cigna, 1 of the Medicare MACs, and 4 Blue Cross Blue Shield plans.

While coverage for OCD treatment may be limited now, NeuroStar is working diligently on expanding access to coverage. The NeuroStar Reimbursement Team has been working hard on developing helpful tools to operationalize OCD treatment for your patients and to drive awareness of this new indication!

Please contact your NeuroStar Reimbursement Manager for more information

[CHECK INSURANCE COVERAGE](#)

TRAKSTAR TIP OF THE MONTH

Spending too much time reviewing and signing-off on individual treatment sessions? You can now review and sign-off on multiple sessions and patients all at once when you access the Unsigned Reports page in TrakStar.

[Get to this feature by clicking Tools > Practice > Unsigned Reports.](#)

Take a few minutes to tell us how we can improve your TrakStar Experience by taking the survey!

[TRAKSTAR USABILITY SURVEY](#)

NEUROSTAR IN THE NEWS

Neuronetics, manufacturer of NeuroStar, has been named the 2022 bronze winner for the 2022 Merit Awards HealthTech Category! Merit Awards recognize the businesses, industries, and leaders that are shaping today's world.



[LEARN MORE NOW](#)

MYNEUROSTAR RESOURCES

Treatment Certificate for Your Patients



Show your patients how much they have improved after completing a full course of NeuroStar treatment by providing them with a certificate showing their PHQ-9 score at the beginning of treatment vs. their PHQ-9 score after finishing 36 treatments. Personalize the certificate on [myneurostar.com](#)!

[PRINT THE CERTIFICATE](#)

Seasonal Depression

Check in with your patients as we start to transition into the cold, winter months. Some people may start to experience some sadness so it's important for you and your patients to be aware of their symptoms.

"Be conscious of when you might need retreatment – bad thoughts and etc. Everyone is different, but you need to be aware." ~ Author of 3,000 Pulses Later and NeuroStar Patient Advocate, Martha Rhodes.

[GET THE TEMPLATE](#)

November's organic social media content is available now and includes a post for OCD. Share with your patients on your social platforms!

[START SHARING TODAY](#)

CO-OP MARKETING

59 days left!

59 days are left until the end of Q4, October 1st – December 31st. Make sure to submit your co-branded ads for pre-approval as soon as possible to [co-opmarketing@neurostar.com](#).


Pre-approval guarantees reimbursement on your co-branded advertising!

[CO-OP AD CHECKLIST](#)

Reminder: All co-op marketing reimbursement submissions for co-branded ads run in Q3 (July 1st – Sept. 30th) are due no later than November 15th.

Email your submissions to [co-opmarketing@neurostar.com](#).

[CO-OP REIMBURSEMENT CHECKLIST](#)



Let's stay connected!

Tap here to follow NeuroStar today.

Star Connection

Stay tuned for December's edition of Star Connection featuring a special patient advocate. If you would like additional people in your practice to receive this newsletter, please contact your PDM or SAM.

Depression isolates. NeuroStar connects.



NeuroStar Advanced Therapy is only available by prescription. A doctor can help decide if NeuroStar Advanced Therapy is right for you. Patients' results may vary.

The NeuroStar Advanced Therapy system is indicated for the treatment of depressive episodes and for decreasing anxiety symptoms for those who may exhibit comorbid anxiety symptoms in adult patients suffering from Major Depressive Disorder (MDD) and who failed to achieve satisfactory improvement from previous antidepressant medication treatment in the current episode.

The NeuroStar Advanced Therapy system is intended to be used as an adjunct for the treatment of adult patients suffering from Obsessive-Compulsive Disorder (OCD).

Visit [neurostar.com](#) for full safety and prescribing information.

F0-51075-008 Rev A

Unsubscribe